On Thursday, 1 September, the Committee for Medicinal Products for Human Use (CHMP) in the European Medicines Agency (EMA) issued two recommendations in favour of conditional marketing authorisation for two Covid-19 vaccines that have been adapted to the Omicron variant.
These vaccines are the Comirnaty vaccine developed by pharmaceutical companies Pfizer and BioNtech and the Spikevax vaccine developed by Moderna. These two messenger RNA vaccines have been adapted in order to provide...